afoxolaner 136 MG Chewable Tablet [NexGard]

Known as: NexGard 136 MG Chewable Tablet, afoxolaner 136 mg ORAL TABLET, CHEWABLE [NexGard] 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2016-2018
02420162018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
BACKGROUND Safety and efficacy of the combined monthly use of spot-on fipronil 6.76% w/v / permethrin 50.48% w/v (Frontline Tri… (More)
  • table 1
  • table 3
  • table 2
  • table 4
  • table 5
Is this relevant?
2017
2017
The efficacy of a monthly oral endectocide product, NexGard Spectra® (Merial), a combination of afoxolaner and milbemycin oxime… (More)
  • table 2
  • table 3
  • table 5
  • table 4
Is this relevant?
2017
2017
A fixed-combination chewable tablet incorporating afoxolaner plus milbemycin oxime (NexGard Spectra®, Merial) was tested in… (More)
  • table 1
Is this relevant?
2017
2017
The pharmacokinetics of afoxolaner and milbemycin oxime (A3 and A4 forms) in dogs were evaluated following the oral… (More)
Is this relevant?
2016
2016
2016
The efficacy of oral afoxolaner plus milbemycin oxime combination chewables against induced gastrointestinal nematode infections… (More)
Is this relevant?
2016
2016
Afoxolaner (AFX) plus milbemycin oxime (MO) combination chewable tablets (NexGard Spectra®, Merial) were evaluated for safety and… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 6
Is this relevant?
2016
2016
The efficacy of afoxolaner plus milbemycin oxime (AFX + MO) combination chewables (NexGard Spectra®, Merial) and AFX single… (More)
  • table 1
  • table 2
Is this relevant?
2016
2016
Infection of dogs with the cardiopulmonary nematode Angiostrongylus vasorum may result in severe clinical disease therefore… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
Is this relevant?